NCT06219356

A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 110 (estimated)
• Sponsor: Hangzhou GluBio Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Study GLB-002-01 is a first-in-human (FIH), phase 1, open-label, dose escalation and expansion clinical study, the purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-002 monotherapy in participants with relapsed or refractory Non-Hodgkin lymphomas (R/R NHL).

Conditions

• Non-Hodgkin Lymphoma

Interventions

Type	Name	Description
DRUG	GLB-002	Administered orally according to the assigned treatment schedule.

Timeline

• Start date: 2024-01-11
• Primary completion: 2026-01-31
• Completion: 2027-02-28
• First posted: 2024-01-23
• Last updated: 2025-08-19

Locations

13 sites across 1 country: China